title: [Regrowth of Isolated Local Residual Tumor Effectively Treated with Chemoradiotherapy More Than Five Years after a Resection for Pancreatic Cancer with an Involvement of the Portal Vein].
abstract: A 55-year-old man who presented with abdominal pain was diagnosed with pancreatic head cancer involving the portal vein. He underwent pylorus-preserving pancreaticoduodenectomy without a resection of the portalvein, resulting in a macroscopic residualtumor, because radicalresection was impossible owing to the severe localinvasion. Postoperative chemotherapy( GEM plus S-1)was administered. The tumor size decreased and CA19-9 values normalized. Five years after the resection, chemotherapy was stopped. The regrowth of an isolated local residual tumor without a distant metastasis was diagnosed 65 months after the resection. He underwent chemoradiotherapy(CRT)with S-1. The size of the tumor remained stable, but FDG-PET demonstrated a disappearance of high FDG uptake in the tumor and CA19-9 values normalized. We reported a case in which CRT was an effective treatment for the regrowth of localresidualtumor after resection for pancreatic cancer.
authors.affiliation: Dept. of Surgery, Kashiwa Kousei General Hospital.
authors.forename: Tomonori
authors.initials: T
authors.lastname: Matsumura
authors.forename: Eishi
authors.initials: E
authors.lastname: Totsuka
authors.forename: Kenta
authors.initials: K
authors.lastname: Kitamura
authors.forename: Keigo
authors.initials: K
authors.lastname: Okada
authors.forename: Satoshi
authors.initials: S
authors.lastname: Inose
authors.forename: Motoi
authors.initials: M
authors.lastname: Koyama
authors.forename: Naokazu
authors.initials: N
authors.lastname: Nakamura
authors.forename: Shigeru
authors.initials: S
authors.lastname: Masamura
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Karikomi
authors.forename: Tatsushi
authors.initials: T
authors.lastname: Suwa
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D059248:Chemoradiotherapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004338:Drug Combinations; D006801:Humans; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000628:therapy; D010094:Oxonic Acid / Q000008:administration & dosage; D010190:Pancreatic Neoplasms / Q000098:blood supply / Q000473:pathology / Q000628:therapy*; D016577:Pancreaticoduodenectomy; D011169:Portal Vein / Q000473:pathology*; D005641:Tegafur / Q000008:administration & dosage; D000093542:Gemcitabine
chemical_list: D004338:Drug Combinations; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000093542:Gemcitabine